AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.
JMCP May 2025 Issue
In this Issue
Research
Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States
L. Liu, J. Cui, M. Neidecker, and M. Nahata
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema
J. Chambers, M. Beinfeld, T. Richardson, and M. Pangrace
Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hypertension
K. Callaway Kim, E. Roberts, J. Donohue, C. Good, L. Sabik, J. Devine, M. Tadrous, and K. Suda
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia
A. Chanan-Khan, K. Hanna, M. Xue, M. Massoudi, M. Balk, R. Gani, H. Zivari Piran, and K. Yang
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues
C. Young, S. Phares, A. Kennedy, J. Sullivan, B. McGowan, and M. Trusheim
Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States
M. Yaghoubi, H. Jiang, R. Casciano, C. Ngai, and Mit Patel
Research Brief
The influence of medication adherence on Medicare Star Ratings: A decade-long analysis of health plan performance
E. Borrelli, P. Saad, N. Barnes, and J. Lucaci
Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023
D. Do, T. Lee, S. Peasah, A. Inneh, U. Patel, and C. Good
COMPLETE ISSUE
JMCP, May 2025, Volume 31, Number 5
Related
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
